A Study of LY317615 in Patients With Brain Tumors

Phase 2

Completed

• Conditions: Malignant Glioma

• Registration Number: NCT00190723
• Lead Sponsor: Eli Lilly and Company

Brief Summary

1. The safety of LY317615 and any side effects that might be associated with the drug.

2. Whether LY317615, can help patients with brain tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-10
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Study Completion: 2006-12
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-24
• Last Update Posted: 2007-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• You must be at least 18 years old
• You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
• You must be able to swallow the LY317615 tablets

Exclusion Criteria

• You are a woman who is pregnant or breastfeeding
• In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.

Secondary Outcome Measures

Name	Time	Method
To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician; 🇺🇸 Bethesda, Maryland, United States